MRL Ventures is Merck’s independent early-stage therapeutics venture capital fund.
The MRL Venture Fund is the Cambridge, MA – based independent venture capital investment group within Merck Research Laboratories, the R&D division of Merck & Co., Inc. MRL Ventures creates and/or invests in seed and early-stage therapeutics companies, based on translatable breakthrough science, with the potential to deliver highly differentiated new medicines to improve human health.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 21, 2022
Carisma Therapeutics
|
Series C | $30M | Biotechnology | — |
Mar 31, 2021
Entrada Therapeutics
|
Series B | $116M | Biotechnology | — |
Mar 1, 2021
Carisma Therapeutics
|
Series B | $12M | Biotechnology | — |
Jan 7, 2021
Carisma Therapeutics
|
Series B | $47M | Biotechnology | — |
Oct 6, 2019
LabCentral
|
Corporate Round | $13M | Education | — |